Clinical trial
Nicotinic Receptor Augmentation of SSRI Antidepressants
NCT00319319 · Yale University, Other · Completed
Key facts
| NCT number | NCT00319319 |
|---|---|
| Title | Nicotinic Receptor Augmentation of SSRI Antidepressants |
| Official title | A Double-Blind,Randomized,Placebo-Controlled Trial of Mecamylamine Hydrochloride for the Treatment of SSRI-Refractory Major Depressive Disorder. |
| Lead sponsor | Yale University, Other |
| Collaborators | Donaghue Medical Research Foundation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Depressive Disorder |
| Intervention type | Drug |
| Interventions | Mecamylamine hydrochloride (Inversine) |
| Enrollment | 60 |
| Start date | Jan 1, 2003 |
| Completion | Jan 1, 2007 |
| First posted | Apr 27, 2006 |
| Last update posted | Apr 19, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: